Paying for quality has become a popular catch phrase and solution to the drug shortage problem, but Christine Baeder, the recently departed chief operating officer for US generics and biosimilar at Teva Pharmaceutical Industries Ltd., worries the current proposals won’t actually live up to the hype and could harm more than help the generic industry.
Baeder spoke to Pink Sheet on the sidelines of the Milken Institute Future of Health Summit in November, just weeks before her departures from Teva and the Association for Accessible...